Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Income from Continuing Operations (2020 - 2023)

Terns Pharmaceuticals' Income from Continuing Operations history spans 4 years, with the latest figure at 21019000.0 for Q4 2023.

  • For Q4 2023, Income from Continuing Operations fell 32.85% year-over-year to 21019000.0; the TTM value through Dec 2023 reached 90210000.0, down 49.49%, while the annual FY2025 figure was 610000.0, 100.68% up from the prior year.
  • Income from Continuing Operations reached 21019000.0 in Q4 2023 per TERN's latest filing, up from 29767000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 31009000.0 in Q4 2020 to a low of 29767000.0 in Q3 2023.
  • Average Income from Continuing Operations over 4 years is 12521250.0, with a median of 13851500.0 recorded in 2022.
  • The largest YoY upside for Income from Continuing Operations was 2.11% in 2021 against a maximum downside of 145.93% in 2021.
  • A 4-year view of Income from Continuing Operations shows it stood at 31009000.0 in 2020, then crashed by 145.93% to 14242000.0 in 2021, then dropped by 11.09% to 15822000.0 in 2022, then plummeted by 32.85% to 21019000.0 in 2023.
  • Per Business Quant, the three most recent readings for TERN's Income from Continuing Operations are 21019000.0 (Q4 2023), 29767000.0 (Q3 2023), and 17896000.0 (Q2 2023).